爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

syri pharma limited t/a thame laboratories - amitriptyline hydrochloride - oral solution - 50 mg/5ml - non-selective monoamine reuptake inhibitors; amitriptyline

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

abc petrie pty ltd - 35177 - mask, surgical, single use - mask designed to be placed over the mouth and nose of a healthcare professional, permitting normal breathing whilst preventing the bi-directional flow of microorganisms.

马耳他 - 英文 - Medicines Authority

wockhardt uk limited - amitriptyline hydrochloride - oral solution - amitriptyline hydrochloride 25 milligram(s)/5 millilitre - psychoanaleptics

马耳他 - 英文 - Medicines Authority

wockhardt uk limited - amitriptyline hydrochloride - oral solution - amitriptyline hydrochloride 50 milligram(s)/5 millilitre - psychoanaleptics

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

genzyme australasia pty ltd - alemtuzumab -

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - amitriptyline hydrochloride - oral solution - 5mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - amitriptyline hydrochloride - oral solution - 10mg/1ml

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - nortriptyline hydrochloride - film-coated tablet - 10 milligram(s) - non-selective monoamine reuptake inhibitors; nortriptyline

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

chanelle medical unlimited company - nortriptyline hydrochloride - film-coated tablet - 25 milligram(s) - non-selective monoamine reuptake inhibitors; nortriptyline

美国 - 英文 - NLM (National Library of Medicine)

janssen biotech, inc. - abciximab (unii: x85g7936gv) (abciximab - unii:x85g7936gv) - abciximab 2 mg in 1 ml - abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications - in patients undergoing percutaneous coronary intervention - in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours safety and efficacy of abciximab use in patients not undergoing percutaneous coronary intervention have not been established. abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in clinical studies. because abciximab may increase the risk of bleeding, abciximab is contraindicated in the following clinical situations: - active internal bleeding - recent (within six weeks) gastrointestinal (gi) or genitourinary (gu) bleeding of clinical significance - history of cerebrovascular accident (cva) within two years, or cva with a significant residual neurological deficit - bleeding diathesis - administration of oral anticoagulan